This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management

Authoring team

Treatment is symptomatic, and includes:

  • skin: calamine lotion and topical anaesthetics
  • eyes: steroid drops, with referal to ophthalmologists for assessment
  • systemic antibiotics are indicated if there are any features of infection There may be a role for systemic steroids (controversial) (1) - discuss with a dermatologist. Benefits of intravenous immunoglobulin treatment in Stevens-Johnson syndrome have been documented in some studies (1).

With respect to systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome (2):

  • found when compared to corticosteroids, etanercept may result in mortality reduction
  • certainty of evidence for disease-specific mortality is very low for corticosteroids versus no corticosteroids, IVIG (intravenous immunoglobulins) versus no IVIG and cyclosporin versus IVIG

Reference:

  • 1. Davis M.D.P. Picture of the Month-Diagnosis. Arch Pediatr Adolesc Med. 2006;160:802
  • 2. Jacobsen A, Olabi B, Langley A, Beecker J, Mutter E, Shelley A, Worley B, Ramsay T, Saavedra A, Parker R, Stewart F, Pardo Pardo J. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD013130. DOI: 10.1002/14651858.CD013130.pub2

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.